Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Teva Pharmaceutical Industries Limited

< Previous 1 2 3 4 5 Next >
Teva to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Teva Pharmaceutical Industries Limited
Via Business Wire
Tickers TEVA
Teva and Biolojic Design Announce Exclusive License Agreement for the Development of a Therapeutic Antibody for Atopic Dermatitis and Asthma
From Teva Pharmaceutical Industries Limited
Via Business Wire
Tickers TEVA
New Post Hoc Phase 3 Data Analysis Shows AJOVY® (fremanezumab) Reduced Migraine Attacks in Adults with Migraine and Co-morbid Obesity
From Teva Pharmaceutical Industries Limited
Via Business Wire
Tickers TEVA
Teva Completes Closing of Exclusive Collaboration Deal to Deliver Inflammatory Bowel Disease Treatment
From Teva Pharmaceutical Industries Limited
Via Business Wire
Tickers SNY TEVA
Teva to Present at the 6th Annual Evercore ISI HealthCONx Conference
From Teva Pharmaceutical Industries Limited
Via Business Wire
Tickers TEVA
Teva Announces Approval of a Generic Version of Forteo® (teriparatide injection), in the U.S.
From Teva Pharmaceutical Industries Limited
Via Business Wire
Tickers TEVA
Teva and Royalty Pharma Collaborate to Further Accelerate Olanzapine LAI Program
From Teva Pharmaceutical Industries Limited
Via Business Wire
Tickers RPRX TEVA
Teva Reports Third Quarter 2023 Financial Results and Increases Revenue Guidance
From Teva Pharmaceutical Industries Limited
Via Business Wire
Tickers TEVA
Teva appoints new CEO for Teva api, its Active Pharmaceutical Ingredients Business
From Teva Pharmaceutical Industries Limited
Via Business Wire
Tickers TEVA
Teva to Present New Data Supporting Safety, Efficacy and Real-World Effectiveness of AUSTEDO® (deutetrabenazine) Tablets at the 2023 HSG Annual Meeting
From Teva Pharmaceutical Industries Limited
Via Business Wire
Tickers TEVA
UZEDY™ (risperidone) Extended-Release Injectable Suspension Significantly Prolongs Time to Schizophrenia Relapse in RISE Study Results Published in The Lancet Psychiatry
From Teva Pharmaceutical Industries Limited
Via Business Wire
Tickers TEVA
Teva to Provide Second Round of Funding to Clinics in California, Florida and New Jersey as Part of $2 Million Commitment Through Community Routes: Access to Mental Health Care Program
From Teva Pharmaceutical Industries Limited
Via Business Wire
Tickers TEVA
Teva Phase IV UNITE Study Shows AJOVY® (fremanezumab) Reduced Migraine Attacks and Depression Symptoms in Migraine Sufferers with Major Depressive Disorder
From Teva Pharmaceutical Industries Limited
Via Business Wire
Tickers TEVA
Teva to Host Conference Call to Discuss Third Quarter 2023 Financial Results at 8 a.m. ET on November 8, 2023
From Teva Pharmaceutical Industries Limited
Via Business Wire
Tickers TEVA
Sanofi and Teva Announce Exclusive Collaboration to Deliver Inflammatory Bowel Disease Treatment
From Teva Pharmaceutical Industries Limited
Via Business Wire
Tickers SNY TEVA
Teva Announces Changes to Executive Management Team
From Teva Pharmaceutical Industries Limited
Via Business Wire
Tickers TEVA
Teva to Present at the 21st Annual Morgan Stanley Global Healthcare Conference
From Teva Pharmaceutical Industries Limited
Via Business Wire
Tickers TEVA
Teva to Present Data for AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets, AUSTEDO® (deutetrabenazine) Tablets and UZEDY™ (risperidone) Extended-Release Injectable Suspension at Psych Congress 2023
From Teva Pharmaceutical Industries Limited
Via Business Wire
Tickers TEVA
Teva Settles Price Fixing Charges With U.S. DOJ
From Teva Pharmaceutical Industries Limited
Via Business Wire
Tickers TEVA
Teva Reports Second Quarter 2023 Financial Results
From Teva Pharmaceutical Industries Limited
Via Business Wire
Tickers TEVA
Teva Announces Appointment of Dr. Angus Grant to Executive Vice President, Business Development
From Teva Pharmaceutical Industries Limited
Via Business Wire
Tickers TEVA
Teva Pharmaceuticals and Alvotech Provide Update on Strategic Biosimilars Partnership
From Teva Pharmaceutical Industries Limited
Via Business Wire
Tickers TEVA
Teva to Host Conference Call to Discuss Second Quarter 2023 Financial Results at 8 a.m. ET on August 2, 2023
From Teva Pharmaceutical Industries Limited
Via Business Wire
Tickers TEVA
Teva’s 3rd interim analysis of PEARL real-world study on AJOVY® (fremanezumab) reveals sustained long-term effectiveness in reducing frequency, duration and severity of attacks in patients with chronic and episodic migraine
From Teva Pharmaceutical Industries Limited
Via Business Wire
Tickers TEVA
Teva to Present Data at the 2023 American Headache Society Annual Scientific Meeting Demonstrating AJOVY® (fremanezumab-vfrm) Injection Significantly Reduced Migraine and Depression Symptoms in Patients
From Teva Pharmaceutical Industries Limited
Via Business Wire
Tickers TEVA
Teva Reaches Agreement With Kentucky to Settle the State’s Price Fixing Claims
From Teva Pharmaceutical Industries Limited
Via Business Wire
Tickers TEVA
Alvotech and Teva Secure U.S. License Date for AVT04, a Proposed Biosimilar to Stelara®
From Teva Pharmaceutical Industries Limited
Via Business Wire
Tickers ALVO TEVA
Teva Concludes Nationwide Opioids Settlement Agreement
From Teva Pharmaceutical Industries Limited
Via Business Wire
Tickers TEVA
Teva Presents Real-World Data for AUSTEDO® (deutetrabenazine) Tablets with 4-Week Patient Titration Kit at Psych Congress Elevate 2023
From Teva Pharmaceutical Industries Limited
Via Business Wire
Tickers TEVA
Teva to Present Data Demonstrating UZEDY™ (risperidone) Extended-Release Injectable Suspension Significantly Prolonged Time to Impending Relapse for Adults with Schizophrenia at the American Psychiatric Association’s 2023 Annual Meeting
From Teva Pharmaceutical Industries Limited
Via Business Wire
Tickers TEVA
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.